Cargando…

P-gp and taxanes

Detalles Bibliográficos
Autores principales:	Hendrikx, Jeroen J.M.A., Beijnen, Jos H., Schinkel, Alfred H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278324/ https://www.ncbi.nlm.nih.gov/pubmed/25594047

Ejemplares similares

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
por: van Eijk, Maarten, et al.
Publicado: (2019)

Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites
por: F. Martins, Margarida L., et al.
Publicado: (2022)

Fixed Dosing of Monoclonal Antibodies in Oncology
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2017)

The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
por: Loos, Nancy H. C., et al.
Publicado: (2022)

The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins
por: Loos, Nancy H.C., et al.
Publicado: (2023)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
por: Hendrikx, Jeroen J M A, et al.
Publicado: (2020)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

No relation between docetaxel administration route and high‐grade diarrhea incidence
por: Hendrikx, Jeroen J. M. A., et al.
Publicado: (2020)

P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)
por: Wang, Yaogeng, et al.
Publicado: (2021)

Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography–tandem mass spectrometry
por: Susam, M. Merve, et al.
Publicado: (2022)

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability
por: Li, Wenlong, et al.
Publicado: (2021)

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure
por: Wang, Jing, et al.
Publicado: (2022)

Targeting LIM kinases in taxane resistant tumors
por: Prunier, Chloé, et al.
Publicado: (2016)

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
por: Martínez-Chávez, Alejandra, et al.
Publicado: (2019)

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
por: Hendrikx, J J M A, et al.
Publicado: (2014)

Is GP-led follow-up feasible?
por: Francken, A B, et al.
Publicado: (2010)

Glutathione S-transferases (GSTs) polymorphism and taxane (docetaxel) sensitivity in breast cancer
por: Lee, Anbok
Publicado: (2019)

Automated synthesis and quality control of [(99m)Tc]Tc-PSMA for radioguided surgery (in a [(68)Ga]Ga-PSMA workflow)
por: Aalbersberg, Else A., et al.
Publicado: (2020)

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein
por: Asperen, J van, et al.
Publicado: (1999)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
por: Damoiseaux, David, et al.
Publicado: (2022)

Mechanisms of Taxane Resistance
por: Maloney, Sara M., et al.
Publicado: (2020)

Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?
por: Pérez-García, José, et al.
Publicado: (2012)

A physiologically based pharmacokinetic model for [(68)Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients
por: Siebinga, Hinke, et al.
Publicado: (2023)

Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge
por: Anoop, T M, et al.
Publicado: (2022)

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
por: van Asperen, J., et al.
Publicado: (1997)

Improving Appropriate Prescribing For Geriatric Patients Using a Clinical Decision Support System
por: van den Hanenberg, Floor, et al.
Publicado: (2022)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
por: Kianersi, Shirin, et al.
Publicado: (2023)

‘Et tu, inhibitor?’: the potential for HIV inhibitors to prime P-gp-mediated chemoresistance in cancer
por: Shull, Austin Y, et al.
Publicado: (2017)

Improving GP registration and access for migrant health
por: Ciftci, Yusuf, et al.
Publicado: (2022)

Taxane-Induced Peripheral Neurotoxicity
por: Velasco, Roser, et al.
Publicado: (2015)

Sex Differences in Taxane Toxicities
por: Chmielewski, Nicole N., et al.
Publicado: (2022)

GP96: safeguarding Treg
por: Zhang, Yongliang, et al.
Publicado: (2015)

Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
por: Siebinga, Hinke, et al.
Publicado: (2022)

Predicting [(177)Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [(68)Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
por: Siebinga, Hinke, et al.
Publicado: (2023)

Taxanes for the Treatment of Metastatic Breast Cancer
por: Gradishar, W.J.
Publicado: (2012)

Structural insight into the stabilization of microtubules by taxanes
por: Prota, Andrea E, et al.
Publicado: (2023)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dqdboshd8jtceurehvnbnj0m1q